DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Omalizumab
Omalizumab
Xolair/Omalizumab
(Human) ELISA Kit Rev 06/20 (Catalog # E 4381 - 100, 100 Assays, Store at 4°C) I
Omalizumab, Xolair
Immunopharmacology: a Guide to Novel Therapeutic Tools - Francesco Roselli, Emilio Jirillo
XOLAIR Prescribing Information
Recommendation for Optimal Management of Severe Refractory Asthma
Monoclonal Antibodies in Treating Food Allergy: a New Therapeutic Horizon
XOLAIR® (Omalizumab) for Injection NDC 50242-040-62
B Cells and Antibodies As Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders
INN Working Document 05.179 Update 2011
Table of Contents
A104.2.Full.Pdf
Sustained Efficacy and Safety of Adalimumab in Psoriasis Treatment
(INN) for Biological and Biotechnological Substances
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
The Anti-Ige Mab Omalizumab Induces Adverse Reactions by Engaging Fcγ Receptors
Antibody Drug Nomenclature: -Umab -Zumab -Ximab
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
Top View
BIOSIMILARS for RHEUMATOID ARTHRITIS an Experienced Partner Can Foresee Your Biosimilar Development Challenges
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Omalizumab (Xolair®)
Review and Feature Articledrug-Induced Paradoxical Vocal Fold Motion
Dermatologic Toxicities Associated with Immunotherapies and Management Strategies
Dmards = DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
XOLAIR® (Omalizumab) for Injection NDC 50242-040-62
Datasheet: HCA235
Role of Biologics in the Management of Asthma
Monoclonal Antibodies in Asthma Therapy
Medical Policy Update Bulletin: August 2021
Xolair Label
Xolair® (Omalizumab)
Xolair, INN-Omalizumab
Customs Tariff - Schedule Xxi - 1
Guide for Recommencing Immunosuppression/Dmards Post COVID-19
Omalizumab in Allergic Diseases, a Recent Review
(Human) ELISA Kit 07/20 (Catalog # E485 7- 100, 96 Assays, Store at 4°C) I